h3n2 influenza viral

3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3].

Anti-Influenza agent 10 (Compound 41) is an inhibitor of the RNA-dependent RNA polymerase (RdRp) of the influenza A virus. It shows potent antiviral activity against the A/PR/8/34(H1N1) strain, with an IC50 of 0.29 μM and a KD of 4.11 μM. The compound functions by disrupting the interaction between the PA and PB1 subunits, inhibiting the assembly of the viral RdRp complex, and thereby blocking transcription and replication of the viral genome. Anti-Influenza agent 10 also demonstrates significant broad-spectrum efficacy against various influenza strains, such as H3N2, H3N8, and H9N2, with IC50 values of 3.96, 1.91, and 1.45 μM, respectively. It is useful for research on influenza A virus infections.

Oseltamivir (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A/H3N2, A/H1N2, A/H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.

Oseltamivir-D3 is a deuterated compound of Oseltamivir. Oseltamivir (T5186L) has a CAS number of 196618-13-0. Oseltamivir (T5186L) (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A/H3N2, A/H1N2, A/H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.